Large observational studies involving tens of thousands of women have found no meaningful increase in breast cancer risk from spironolactone use. The concern dates back decades, rooted partly in animal studies and a now-removed warning on the drug’s FDA label, but human evidence has consistently failed to confirm it. The story is more nuanced than a flat “no risk,” though, because spironolactone does cause real breast-related side effects that can alarm patients and because the drug’s hormonal activity raises legitimate biological questions worth understanding.
Where the Worry Came From
Spironolactone has been in clinical use since the 1960s. It works primarily by blocking aldosterone receptors in the kidneys, which helps lower blood pressure and reduce fluid retention. But its chemical structure resembles steroid hormones, and it also blocks androgen (male sex hormone) receptors. That hormonal crossover is what makes it useful for conditions like hormonal acne and hair loss in women, and it is also what first raised eyebrows about cancer.
Early animal studies, particularly in rats given high doses over long periods, showed increased rates of certain tumors. Those rodent findings prompted the U.S. Food and Drug Administration to include “carcinoma of the breast” on spironolactone’s prescribing label as a possible adverse effect. The label carried that language for years, even though no cause-and-effect relationship had ever been established in humans. The warning made many clinicians and patients uneasy, especially women taking the drug for skin or hair conditions where it might be used for years.
What the Largest Human Studies Found
The most direct evidence comes from a large retrospective study that tracked over 1.29 million women aged 55 and older in a UK primary-care database. Among roughly 28,000 women prescribed spironolactone and about 56,000 matched controls, breast cancer rates were virtually identical: about 0.39% and 0.38% per year, respectively, over a mean follow-up of just over four years. The adjusted hazard ratio was 0.99, meaning spironolactone users had essentially the same risk as non-users.1PubMed Central. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study
An observational postmarketing study using international pharmacovigilance data approached the question from a different angle, comparing adverse-event reports for spironolactone against reports for other drugs and for similar diuretics like amiloride and triamterene. It found no positive association between spironolactone exposure and breast cancer in women 50 and older. In fact, the adjusted reporting odds ratio suggested slightly fewer breast cancer reports with spironolactone compared to these other medications.2PubMed. Breast cancer and spironolactone: an observational postmarketing study
A meta-analysis published in JAMA Dermatology pooled data from three studies and found no statistically significant association between spironolactone and breast cancer overall. The pooled relative risk was 1.04, with a confidence interval that comfortably included 1.0 (no effect). However, this analysis did reveal something worth noting: sensitivity analyses showed that the direction of the finding depended on the type of study. One analysis using odds ratios suggested a slightly lower risk with spironolactone, while analyses using incidence rate ratios suggested a modestly higher risk. The certainty of evidence was rated very low, largely because the populations and methods differed across the included studies.3JAMA Dermatology. Association of Spironolactone Use With Risk of Cancer That kind of inconsistency is common when you are looking at very small effect sizes in observational data, and it is one reason researchers have generally concluded there is no clinically important signal here.
Younger Women Taking Spironolactone for Acne
Most of the older studies focused on women over 55 who were prescribed spironolactone for cardiovascular indications like heart failure or resistant hypertension. That left a gap: what about younger women taking it for acne, who might use the drug for years or even decades? The demographic profile of spironolactone prescribing has shifted considerably, with growing use among younger women for dermatological reasons.
A large matched cohort study addressed this directly by comparing over 50,000 acne patients treated with spironolactone against equal-sized control groups. Compared with patients on non-systemic acne treatments, spironolactone users showed no significant increase in breast cancer risk. When compared against patients prescribed oral tetracyclines (a common alternative for acne), spironolactone users actually had a slightly lower risk of breast malignancy.4Journal of Investigative Dermatology. Spironolactone and Breast Cancer: What’s the Connection? The researchers framed their findings as reassurance that spironolactone could be a valuable acne treatment, particularly as an alternative to long-term antibiotic use, without introducing a breast cancer worry.
The FDA Label Change
Perhaps the clearest institutional signal came in 2018, when the FDA revised the spironolactone drug label and removed “carcinoma of the breast” as a listed possible adverse effect. The old label had included that language without any established cause-and-effect relationship. After decades of accumulating human data showing no convincing link, the warning was dropped.5PubMed Central. Exploring the historical stigma of spironolactone use in breast cancer survivors with alopecia This was a meaningful change, because doctors and patients often rely on the prescribing label when making treatment decisions, and the outdated warning had led to years of unnecessary hesitation.
Even so, the old label language lives on in clinical memory. Some physicians trained during the era when the warning was present still reflexively avoid prescribing spironolactone to women with a personal or family history of breast cancer. That caution is understandable given the stakes, but the evidence basis for it has largely evaporated.
What About Women Who Already Have or Had Breast Cancer
A separate and arguably more important question is whether spironolactone is safe for women who have already been diagnosed with breast cancer. These women often need treatments for conditions like hair loss (alopecia), acne, or high blood pressure, and spironolactone might otherwise be a good option. A retrospective analysis looking specifically at breast cancer recurrence found that spironolactone use was not independently associated with increased recurrence, and the authors suggested it could be considered for treating alopecia in breast cancer survivors.6PubMed. Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis
A related concern is whether spironolactone might interfere with endocrine therapies used to treat hormone receptor-positive breast cancer, drugs like tamoxifen or aromatase inhibitors. A review of the available evidence concluded there is no data supporting such an interaction, and that spironolactone has not been linked to increased breast cancer incidence based on multiple large studies.7PubMed Central. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies Still, these are areas where individual circumstances matter, and oncologists may have patient-specific reasons for caution that go beyond the population-level data.
Benign Breast Effects That Cause Alarm
One reason the breast cancer question keeps coming back is that spironolactone genuinely does cause noticeable breast changes. Breast tenderness, breast pain, and in men, visible breast tissue enlargement (gynecomastia) are among the drug’s most recognized side effects. These are caused by its anti-androgen properties shifting the balance between estrogen and androgen activity in breast tissue.
A pharmacovigilance analysis comparing spironolactone, eplerenone, and finerenone (three drugs in the same class of mineralocorticoid receptor antagonists) found that about 8% of spironolactone adverse-event reports involved sex hormone-related effects. Gynecomastia alone accounted for nearly 300 reported cases, and breast pain and breast tenderness added over 170 more.8Frontiers in Pharmacology. Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024 These are benign effects. They are not precancerous. But when you develop breast swelling or pain while taking a medication, it is entirely natural to worry about cancer, and that worry fuels the question.
Case reports illustrate how this plays out in practice. A man taking spironolactone for a cardiovascular condition developed painful unilateral breast swelling after about a year of use. Within a month of stopping the drug, the pain resolved and the swelling shrank.9PubMed Central. Spironolactone-Induced Unilateral Gynecomastia Similar cases have been documented with bilateral swelling in patients with liver disease.10PubMed Central. Spironolactone-Induced Bilateral Gynecomastia in a Patient With Comorbid Conditions A broad review of drug-induced gynecomastia found that in most cases, the breast tenderness and enlargement resolve on their own after the drug is stopped, and hormonal profiles typically cannot explain the enlargement, suggesting it is driven by the local tissue-level effects of the drug rather than a systemic hormonal shift.11PubMed Central. Gynecomastia and drugs: a critical evaluation of the literature
The distinction between benign breast effects and malignancy matters clinically. Breast pain and gynecomastia from spironolactone are dose-dependent, reversible, and not associated with cancerous transformation. If you develop these symptoms while on spironolactone, talk to your prescriber about whether the dose can be lowered or the drug switched, but it is not a sign you are developing breast cancer.
Why the Drug’s Hormonal Activity Does Not Translate to Cancer Risk
Spironolactone’s anti-androgen activity is well established. It blocks androgen receptors, which is exactly why it helps with hormonal acne and androgen-driven hair loss. Some people assume that blocking androgens must mean boosting estrogen, and since estrogen exposure is a known risk factor for breast cancer, the logic seems to follow. But the biology is not that straightforward.
Spironolactone’s main metabolite, canrenone, has been tested for interactions with estrogen and progesterone receptors. An early study using human uterine tissue found that canrenone did not alter estrogen binding to estrogen receptors.12PubMed Central. The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol In other words, spironolactone does not appear to directly stimulate estrogen receptors in the way that exogenous estrogen would. The breast changes it causes seem to result from shifting the androgen-to-estrogen ratio locally rather than from direct estrogen receptor activation, and that mechanism does not carry the same cancer implications.
Interestingly, preclinical research has explored whether mineralocorticoid receptor antagonists might actually work against breast cancer in some contexts. A laboratory study found that spironolactone and finerenone significantly reduced migration and stemness properties in triple-negative breast cancer cells exposed to aldosterone or a growth factor called TGF-beta-1.13PubMed. Mineralocorticoid and glucocorticoid receptor cooperation drives advanced phenotypes in triple-negative breast cancer This is early-stage work and should not be taken as evidence that spironolactone prevents or treats breast cancer. But it does add to the picture that the drug’s relationship with breast tissue is more complex than “hormonal drug causes cancer.”
How Newer Alternatives Compare
If the breast-related side effects of spironolactone are a dealbreaker, newer mineralocorticoid receptor antagonists offer alternatives with a different side-effect profile. Eplerenone, approved for heart failure and hypertension, is more selective for the mineralocorticoid receptor and has far less anti-androgen activity. In a head-to-head trial, spironolactone caused gynecomastia in about 21% of men and breast pain in about 21% of women, compared with roughly 5% and 0%, respectively, for eplerenone.14Journal of Hypertension. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism The pharmacovigilance comparison confirmed that eplerenone has fewer sex hormone-related adverse events overall, and finerenone, the newest drug in this class, had no sex hormone-related events reported at all.8Frontiers in Pharmacology. Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024
The catch is that eplerenone and finerenone are used primarily for cardiovascular and kidney disease indications. They are not prescribed for acne or hair loss because they lack the anti-androgen activity that makes spironolactone effective for those conditions. For dermatological patients, spironolactone remains the main option in this drug family, which is part of why the breast cancer question is so persistent among this population: there is no easy swap to a less hormonally active version.
Spironolactone in Gender-Affirming Hormone Therapy
Spironolactone is frequently used as an androgen blocker in gender-affirming hormone therapy for transgender women. In this context it is typically combined with estrogen, and the combination does induce breast development, including formation of ducts, lobules, and fat deposition.15PubMed Central. Effects of Hormones on Breast Development and Breast Cancer Risk in Transgender Women The question of breast cancer risk in transgender women on hormone therapy is an active research area, but the evidence so far suggests that spironolactone itself, as opposed to the estrogen component, is not an independent risk factor for breast cancer in this population.
Screening recommendations for transgender women on hormone therapy are still evolving. The breast tissue that develops under hormonal treatment is biologically different from natal breast tissue, and the baseline cancer risk appears lower than in cisgender women, though it is higher than in cisgender men. If you are a transgender woman on spironolactone-containing hormone therapy, breast cancer screening should follow your clinician’s guidance based on your specific risk factors, duration of hormone exposure, and age, rather than generic population guidelines.
Where Uncertainty Still Lives
The honest assessment is that the available evidence is reassuring but not perfect. All of the major studies are observational, meaning they compare groups of people who happened to receive spironolactone with groups who did not, rather than randomly assigning the drug in a controlled experiment. Observational studies can be confounded in ways that are hard to fully adjust for. Women prescribed spironolactone may differ from controls in their health behaviors, their access to screening, or their underlying health conditions, and those differences could mask or mimic a small effect in either direction.
The JAMA Dermatology meta-analysis rated its certainty of evidence as very low, in part because the included studies used different populations and different effect measures, making them difficult to combine cleanly.3JAMA Dermatology. Association of Spironolactone Use With Risk of Cancer Most studies also had follow-up periods of around four to five years, which may not be long enough to detect a cancer risk that takes a decade or more to manifest. And much of the strongest data comes from women over 55 taking the drug for cardiovascular reasons, who may not represent the experience of younger women using it for acne at different doses for different durations.
None of these limitations mean there is a hidden risk lurking. They mean that the question cannot be declared closed with the finality of a randomized controlled trial. What we can say is that multiple large studies, using different methods and different populations, have looked for an association and have not found one. If there were a strong cancer-promoting effect, it would almost certainly have shown up by now.